Sino Biological deposits recombinant Omicron proteins and antibodies to BEI Resources
Posted: 14 January 2022 | Sino Biological Inc. | No comments yet
To support disease research, Sino Biological has deposited reagents for the Omicron variant to BEI Resources.
Credit: Sino Biological
Sino Biological has announced that it has recently deposited reagents for the Omicron variant, including recombinant proteins to Spike and Nucleocapsid, and antibody products to BEI Resources, a central repository for reagents to support infectious disease research. With the addition of the Omicron products to previously deposited array of SARS-CoV-2 reagents, researchers can readily get access to them by registering with BEI Resources.
The table below lists the five Omicron products that will be available in BEI Resources.
|
BEI Item # |
Sino Item # |
Description |
|
NR-56465 |
40592-V08H121 |
SARS-CoV-2 B.1.1.529 (Omicron) Spike RBD Protein (His Tag) |
|
NR-56466 |
40592-MM117 |
SARS-CoV-2 Spike Antibody, Omicron Reactive, Mouse MAb |
|
NR-56478 |
40588-V07E34 |
SARS-CoV-2 B.1.1.529 (Omicron) Nucleocapsid Protein (His Tag) |
|
NR-56479 |
40589-V08H26 |
SARS-CoV-2 B.1.1.529 (Omicron) S1+S2 trimer Protein (ECD, His Tag) |
|
NR-56480 |
40591-V08H41 |
SARS-CoV-2 B.1.1.529 (Omicron) Spike S1 Protein (His Tag) |
Sino Biological is an international biological reagent supplier and service provider. The company specialises in recombinant antigen production and antibody development. The company’s ever-growing portfolio of products includes over 6,000 recombinant proteins, 13,000 antibodies, ELISA assay kits, expression clones, cell culture media and other molecular biology tools. The company also offers a variety of customised services, mainly focusing on recombinant production of antigens and antibodies. Sino Biological is dedicated to virology and infectious disease research. Its newly launched ProVirTM collection is the world’s largest viral antigen bank, carrying over 1,000 viral products from 350 strains of viruses.
Biomarkers aren’t just supporting drug discovery – they’re driving it
FREE market report
From smarter trials to faster insights, this report unpacks the science, strategy and real-world impact behind the next generation of precision therapies.
What you’ll unlock:
- How biomarkers are guiding dose selection and early efficacy decisions in complex trials
- Why multi-omics, liquid biopsy and digital tools are redefining the discovery process
- What makes lab data regulatory-ready and why alignment matters from day one
Explore how biomarkers are shaping early drug development
Access the full report – it’s free!
Related topics
Analysis, Antibodies, Protein, Proteomics, Vaccine
Related conditions
Covid-19
Related organisations
BEI Resources, Sino Biological Inc.
